Thermo Fisher Scientific Inc. (NYSE:TMO) Expected to Earn Q4 2025 Earnings of $5.90 Per Share

Thermo Fisher Scientific Inc. (NYSE:TMO) – Equities research analysts at Zacks Research raised their Q4 2025 EPS estimates for shares of Thermo Fisher Scientific in a note issued to investors on Wednesday, August 14th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings of $5.90 per share for the quarter, up from their previous estimate of $5.30. The consensus estimate for Thermo Fisher Scientific’s current full-year earnings is $21.72 per share.

Several other brokerages have also issued reports on TMO. JPMorgan Chase & Co. lifted their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a report on Thursday, April 25th. Deutsche Bank Aktiengesellschaft increased their price target on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. Robert W. Baird boosted their price objective on Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Barclays cut their price target on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a research note on Friday, June 28th. Finally, TD Cowen raised their price objective on shares of Thermo Fisher Scientific from $648.00 to $658.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Five equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $618.94.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $614.54 on Monday. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $234.75 billion, a PE ratio of 39.42, a price-to-earnings-growth ratio of 2.81 and a beta of 0.77. Thermo Fisher Scientific has a twelve month low of $415.60 and a twelve month high of $622.30. The stock’s 50-day simple moving average is $572.16 and its 200 day simple moving average is $572.87.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, topping the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The firm had revenue of $10.54 billion during the quarter, compared to analysts’ expectations of $10.50 billion. During the same period in the prior year, the company earned $5.15 earnings per share. The company’s quarterly revenue was down 1.4% on a year-over-year basis.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.25%. The ex-dividend date is Friday, September 13th. Thermo Fisher Scientific’s dividend payout ratio is 10.01%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $567.28, for a total value of $5,672,800.00. Following the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $70,238,340.48. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $567.28, for a total value of $5,672,800.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $70,238,340.48. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $600.85, for a total transaction of $180,255.00. Following the transaction, the executive vice president now directly owns 17,887 shares in the company, valued at approximately $10,747,403.95. The disclosure for this sale can be found here. Insiders have sold a total of 33,084 shares of company stock worth $19,767,092 in the last 90 days. Corporate insiders own 0.34% of the company’s stock.

Institutional Trading of Thermo Fisher Scientific

Several hedge funds have recently bought and sold shares of the business. Summa Corp. acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth about $418,000. Private Wealth Management Group LLC purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $110,000. Brookstone Capital Management grew its holdings in Thermo Fisher Scientific by 252.4% during the first quarter. Brookstone Capital Management now owns 4,387 shares of the medical research company’s stock worth $2,550,000 after buying an additional 3,142 shares in the last quarter. Y.D. More Investments Ltd lifted its stake in Thermo Fisher Scientific by 33.9% during the 4th quarter. Y.D. More Investments Ltd now owns 391 shares of the medical research company’s stock valued at $207,000 after acquiring an additional 99 shares in the last quarter. Finally, Private Wealth Partners LLC grew its stake in shares of Thermo Fisher Scientific by 1.0% in the 4th quarter. Private Wealth Partners LLC now owns 85,131 shares of the medical research company’s stock worth $45,187,000 after acquiring an additional 815 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.